Mark Stejbach - 24 Jun 2021 Form 4 Insider Report for Flexion Therapeutics Inc

Role
Director
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
24 Jun 2021
Net transactions value
$0
Form type
4
Filing time
28 Jun 2021, 18:30:40 UTC
Next filing
19 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Award $0 +4,500 +55% $0.000000 12,631 24 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FLXN Stock option (right to buy) Award $0 +7,000 $0.000000 7,000 24 Jun 2021 Common Stock 7,000 $9.22 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.
F2 1,580 shares previously held by The Mark P. Stejbach Revocable Trust UA 07-08-2016 are now held by the Reporting Person directly.
F3 The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant.